References

Tumor-targeted top1 inhibitor delivery with optimized parp inhibition in advanced solid tumors: a phase i trial of gapped scheduling

10.1038/s41467-025-64509-5 · 2025 · External reference

Comprehensive genomic profiles of small cell lung cancer

10.1038/nature14664 · 2015 · External reference

Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data

10.1038/s41568-019-0133-9 · 2019 · External reference

SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures

10.1016/j.celrep.2020.108296 · 2020 · External reference

Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities

10.1016/j.ccell.2020.12.014 · 2021 · External reference

Advancements in Small-cell Lung Cancer: The Changing Landscape Following IMpower-133

10.1016/j.cllc.2018.12.019 · 2019 · External reference

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

10.1016/s0140-6736(19)32222-6 · 2019 · External reference

Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade

10.1016/j.ccell.2024.01.010 · 2024 · External reference

Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies

10.1016/j.cell.2023.12.004 · 2024 · External reference

Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11) Expression with Class I Histone Deacetylase Inhibitors

10.1158/1078-0432.ccr-17-0443 · 2018 · External reference

ASCL1, NKX2-1, and PROX1 co-regulate subtype-specific genes in small-cell lung cancer

10.1016/j.isci.2021.102953 · 2021 · External reference

Cooperative transcriptional regulation of the essential pancreatic islet gene NeuroD1 (beta2) by Nkx2.2 and neurogenin 3

10.1074/jbc.m109.048694 · 2009 · External reference

Pax6 controls the expression of critical genes involved in pancreatic alpha cell differentiation and function

10.1074/jbc.m110.147215 · 2010 · External reference

Semaphorins as emerging clinical biomarkers and therapeutic targets in cancer

10.7150/thno.54023 · 2021 · External reference

POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer

10.1101/gad.314815.118 · 2018 · External reference

A revised airway epithelial hierarchy includes CFTR-expressing ionocytes

10.1038/s41586-018-0393-7 · 2018 · External reference

Basal cell of origin resolves neuroendocrine-tuft lineage plasticity in cancer

10.1038/s41586-025-09503-z · 2025 · External reference

OCA-T1 and OCA-T2 are coactivators of POU2F3 in the tuft cell lineage

10.1038/s41586-022-04842-7 · 2022 · External reference

Tracheal tuft cells release ATP and link innate to adaptive immunity in pneumonia

10.1038/s41467-025-55936-5 · 2025 · External reference

POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC

10.1016/j.jtho.2022.06.004 · 2022 · External reference

A conserved YAP/Notch/REST network controls the neuroendocrine cell fate in the lungs

10.1038/s41467-022-30416-2 · 2022 · External reference

DLL3 regulates Notch signaling in small cell lung cancer

10.1016/j.isci.2022.105603 · 2022 · External reference

MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate

10.1016/j.ccell.2020.05.001 · 2020 · External reference

Small-cell lung cancer: what we know, what we need to know and the path forward

10.1038/nrc.2017.87 · 2017 · External reference

Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties

1985 · External reference

Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer

10.1371/journal.pgen.1005895 · 2016 · External reference

Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer

10.1038/s41467-018-06162-9 · 2018 · External reference

Structural, molecular, and functional insights into Schlafen proteins

10.1038/s12276-022-00794-0 · 2022 · External reference

Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies

10.1016/j.pharmthera.2019.05.009 · 2019 · External reference

Schlafen 11 Expression in Patients With Small Cell Lung Cancer and Its Association With Clinical Outcomes

10.1111/1759-7714.15529 · 2025 · External reference

Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03

10.1016/j.jtho.2024.12.028 · 2025 · External reference

Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

10.1056/nejmoa2307980 · 2023 · External reference

Identification of DLK1, a Notch ligand, as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma

10.1038/s41467-025-60649-w · 2025 · External reference

Combining serum CDK1 with tumor markers for the diagnosis of small cell lung cancer

10.1007/s12094-024-03722-y · 2025 · External reference

Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remission

10.3233/tub-230016 · 2024 · External reference

Significance of achaete-scute complex homologue 1 (ASCL1) in pulmonary neuroendocrine carcinomas; RNA sequence analyses using small cell lung cancer cells and Ascl1-induced pulmonary neuroendocrine carcinoma cells

10.1007/s00418-020-01863-z · 2020 · External reference

Assessment of targets of antibody drug conjugates in SCLC

2025 · External reference

Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers

10.1016/j.jtho.2021.08.763 · 2022 · External reference

Targeting the EZH2-SLFN11 pathway-a lesson in developing molecularly-informed treatments for recurrent small cell lung cancer

10.21037/tcr-24-1755 · 2024 · External reference

Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer

10.1038/s41416-022-01811-9 · 2022 · External reference

SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer

10.21037/tlcr-21-437 · 2021 · External reference

Synergistic Effects of ATR Inhibition and Lurbinectedin in Soft-Tissue Sarcomas: The Predictive Role of SLFN11 Expression

10.1158/1078-0432.ccr-24-2556 · 2025 · External reference

Temozolomide in the Era of Precision Medicine

10.1158/0008-5472.can-16-2983 · 2017 · External reference

ATR inhibition augments the efficacy of lurbinectedin in small-cell lung cancer

10.15252/emmm.202217313 · 2023 · External reference

Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal

10.1126/scisignal.2004088 · 2013 · External reference

Visualizing and interpreting cancer genomics data via the Xena platform

10.1038/s41587-020-0546-8 · 2020 · External reference

GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis

10.1093/nar/gkz430 · 2019 · External reference

UALCAN: An update to the integrated cancer data analysis platform

10.1016/j.neo.2022.01.001 · 2022 · External reference

Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression

10.1093/jnci/djw122 · 2016 · External reference

Challenges of small cell lung cancer heterogeneity and phenotypic plasticity

10.1038/s41568-025-00803-0 · 2025 · External reference

Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer

10.1016/j.ccell.2021.09.008 · 2021 · External reference

Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived models

10.1038/s41467-022-29517-9 · 2022 · External reference

Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer

10.1038/s43018-019-0020-z · 2020 · External reference

Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes

10.21037/tlcr.2018.02.02 · 2018 · External reference

Basal cell of origin resolves neuroendocrine–tuft lineage plasticity in cancer

2024 · External reference

Prognostic Implications of Molecular Subtypes in Primary Small Cell Lung Cancer and Their Correlation With Cancer Immunity

10.3389/fonc.2022.779276 · 2022 · External reference

ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs

10.1016/j.celrep.2016.06.081 · 2016 · External reference

A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer

10.1158/1078-0432.ccr-23-3383 · 2024 · External reference

Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer

10.1186/s13045-023-01464-y · 2023 · External reference

Cancer therapy with antibodies

10.1038/s41568-024-00690-x · 2024 · External reference

ADCdb: the database of antibody-drug conjugates

10.1093/nar/gkad831 · 2024 · External reference

Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer

10.1158/1078-0432.ccr-20-3396 · 2021 · External reference

Analysis of variation of serum CEA, SCC, CYFRA21-1 in patients with lung cancer and their diagnostic value with EBUS-TBNA

10.5937/jomb0-37083 · 2024 · External reference

A comparative study of ProGRP and CEA as serological markers in small cell lung cancer treatment

10.1007/s12672-024-01323-3 · 2024 · External reference

NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING

10.1172/jci185423 · 2025 · External reference

Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer

10.1038/s41467-021-24164-y · 2021 · External reference

Maftools: efficient and comprehensive analysis of somatic variants in cancer

10.1101/gr.239244.118 · 2018 · External reference